Duality Biologics and GSK Enter Exclusive Option Agreement for a Novel Antibody-drug Conjugate (DB-1324)
PRINCETON, N.J., SHANGHAI and SUZHOU, China, Dec. 4, 2024 /PRNewswire/ -- Duality Biologics
{fullname}
About author
You should write because you love the shape of stories and sentences and the creation of different words on a page.
View all posts
Related posts
---
Duality Biologics Announces B7H4 ADC Milestone Achievement and License Exercise by BeiGene
SOMERSET, N.J., SHANGHAI and SUZHOU, China, Dec. 31, 2024 /PRNewswire/ -- Duality Biologics
---
Duality Biologics Announces Expansion of Adcendo ApS Collaboration Through Option Exercise of Strategic License Agreement
Adcendo ApS exercises its option to utilize Duality Biologics' platform to further enhance its
---
Nona Biosciences Announces Update on Its Collaborator DualityBio's Antibody-Drug Conjugate (ADC) Collaboration with BeiGene
CAMBRIDGE, Mass., Jan. 3, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a
